Stock 605199 HAINAN HULUWA PHARMACEUTICAL GROUP CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Hainan Huluwa Pharmaceutical Group Co., Ltd.

Equities

605199

CNE100004223

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-05-26 EDT 		5-day change 1st Jan Change
11.28 CNY -0.27% Intraday chart for Hainan Huluwa Pharmaceutical Group Co., Ltd. -4.65% -25.59%
05-01 Huluwa Pharmaceutical Gets Nod to Register Two Drugs MT
04-26 Hainan Huluwa Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Huluwa Pharmaceutical Gets Nod to Register Two Drugs
MT
Hainan Huluwa Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Huluwa Pharma Gets Nod to Market Terbutaline Sulfate Inhaler
MT
Huluwa Pharma Gets Nod to Register Cefdinir Granules
MT
Huluwa Pharma Registers Ibuprofen Suspension
MT
Huluwa Pharma Registers Hypertension Drug
MT
Hainan Huluwa Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Huluwa Pharmaceutical Gets Nod to Trial Epilepsy Drug
MT
Hainan Huluwa Pharmaceutical Group Co., Ltd.(XSSC:605199) added to S&P Global BMI Index
CI
Hainan Huluwa Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Hainan Huluwa Pharmaceutical Unit Gets Registration Certificate for Allergy Drug in China
MT
Huluwa Pharma's Supplementary Drug Application for Infection Treatment Wins Approval in China
MT
Hainan Huluwa Pharmaceutical Group Co., Ltd. completed the acquisition of 51% stake in Jiangxi Rongxing Pharmaceutical Co., Ltd. from Chen Xuerong.
CI
Hainan Huluwa Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Hainan Huluwa Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Hainan Huluwa Pharmaceutical Group Co., Ltd. entered into an agreement to acquire 51% stake in Jiangxi Rongxing Pharmaceutical Co., Ltd. from Chen Xuerong for CNY 44.88 million
CI
Hainan Huluwa Pharmaceutical Group Co., Ltd.(XSSC:605199) dropped from S&P Global BMI Index
CI
Huluwa Pharmaceutical Gets Regulatory Approval For Drug Production Line in China's Hainan Province
MT
Hainan Huluwa Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Hainan Huluwa Pharmaceutical Unit Acquires Marketing License of 50 Drugs; Shares Up 3%
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 605199 Stock
  4. News Hainan Huluwa Pharmaceutical Group Co., Ltd.